GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Black Diamond Therapeutics Inc (NAS:BDTX) » Definitions » 3-Year Book Growth Rate

Black Diamond Therapeutics (Black Diamond Therapeutics) 3-Year Book Growth Rate : -35.80% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Black Diamond Therapeutics 3-Year Book Growth Rate?

Black Diamond Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $1.99.

During the past 12 months, Black Diamond Therapeutics's average Book Value per Share Growth Rate was -26.10% per year. During the past 3 years, the average Book Value per Share Growth Rate was -35.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 7 years, the highest 3-Year average Book Value per Share Growth Rate of Black Diamond Therapeutics was -35.80% per year. The lowest was -35.80% per year. And the median was -35.80% per year.

Competitive Comparison of Black Diamond Therapeutics's 3-Year Book Growth Rate

For the Biotechnology subindustry, Black Diamond Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Black Diamond Therapeutics's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Black Diamond Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Black Diamond Therapeutics's 3-Year Book Growth Rate falls into.


Black Diamond Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Black Diamond Therapeutics  (NAS:BDTX) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Black Diamond Therapeutics 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Black Diamond Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Black Diamond Therapeutics (Black Diamond Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Black Diamond Therapeutics Inc (NAS:BDTX) » Definitions » 3-Year Book Growth Rate
Comparable Companies
SGMO KPTI ABEO OCGN GMDA NYMXF MNOV ALDX RLMD HOWL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
One Main Street, 14th Floor, Cambridge, MA, USA, 02142
Website
https://www.blackdiamondtherapeutics.com
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-189 and BDTX-1535.
Executives
Biotech Growth N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Ra Capital Nexus Fund, L.p. director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ali Behbahani director, 10 percent owner 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Peter Kolchinsky director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
David M. Epstein director, officer: See Remarks OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE NY 11747
Sergey Yurasov officer: CHIEF MEDICAL OFFICER C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E., SUITE 310, SEATTLE WA 98102
Elizabeth Buck officer: CHIEF SCIENTIFIC OFFICER C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Erika Jones officer: SEE REMARKS C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Fang Ni officer: SEE REMARKS C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Biotech Ag Bb 10 percent owner SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Wendy L Dixon director
Mark A. Velleca director 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Brent Hatzis-schoch officer: See Remarks C/O RADIUS HEALTH, INC., 950 WINTER STREET, WALTHAM MA 02451